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Early decompressive 
hemicraniectomy in thrombolyzed 
acute ischemic stroke patients 
from the international 
ENCHANTED trial
Chao Xia1,2,3, Xia Wang3, Richard I. Lindley4,5, Candice Delcourt3,5,6, Xiaoying Chen3,5, 
Zien Zhou3,7, Rui Guo2, Cheryl Carcel3,5,8, Alejandra Malavera3, Zeljka Calic3, Grant Mair9, 
Joanna M. Wardlaw9, Thompson G. Robinson10 & Craig S. Anderson3,5,8,11,12*
Decompressive hemicraniectomy (DHC) can improve outcomes for patients with severe forms of acute 
ischemic stroke (AIS), but the evidence is mainly derived from non-thrombolyzed patients. We aimed 
to determine the characteristics and outcomes of early DHC in thrombolyzed AIS participants of the 
international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). Post-
hoc analyses of ENCHANTED, an international, partial-factorial, open, blinded outcome-assessed, 
controlled trial in 4557 thrombolysis-eligible AIS patients randomized to low- versus standard-dose 
intravenous alteplase (Arm A, n = 2350), intensive versus guideline-recommended blood pressure 
control (Arm B, n = 1280), or both (Arms A + B, n = 947). Logistic regression models were used to 
identify baseline variables associated with DHC, with inverse probability of treatment weights 
employed to eliminate baseline imbalances between those with and without DHC. Logistic regression 
was also used to determine associations of DHC and clinical outcomes of death/disability, major 
disability, and death (defined by scores 2–6, 3–5, and 6, respectively, on the modified Rankin scale) 
at 90 days post-randomization. There were 95 (2.1%) thrombolyzed AIS patients who underwent 
DHC, who were significantly younger, of non-Asian ethnicity, and more likely to have had prior 
lipid-lowering treatment and severe neurological impairment from large vessel occlusion than other 
patients. DHC patients were more likely to receive other management interventions and have poor 
functional outcomes than non-DHC patients, with no relation to different doses of intravenous 
alteplase. Compared to other thrombolyzed AIS patients, those who received DHC had a poor 
prognosis from more severe disease despite intensive in-hospital management.
Stroke is a leading cause of premature loss of productive life, estimated to have caused several million deaths 
worldwide in 2017, half due to acute ischemic stroke (AIS)1. Reperfusion therapy with intravenous thrombolysis 
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(i.e. recombinant tissue plasminogen activator [rt-PA] or alteplase) and more recently endovascular clot retrieval 
(EVT) are now standard treatments that can improve the chances of functional recovery when administered 
within several hours of symptom  onset2. However, thrombolysis has more limited utility in AIS due to large 
vessel occlusion, EVT is not widely available, and the benefits of both are offset by increased risks of intracranial 
hemorrhage (ICH)3–5. In patients with malignant hemispheric AIS, particularly those presenting late or unable 
to access mechanical thrombectomy, decompressive hemicraniectomy (DHC) has also been shown to improve 
outcomes from reducing intracranial pressure and preventing brain  herniation6. However, the evidence for the 
benefits of DHC has mainly been derived from trials of young to middle-aged non-thrombolyzed adults with 
cerebral edema and mass effect from hemispheric  AIS7–11, and there is limited data on outcomes from early DHC 
after intravenous thrombolysis in a broader range of patients where the risk of ICH from the treatment and sur-
gery are high. Moreover, as access to, and criteria for, the use of DHC in AIS varies widely within and between 
countries, there is uncertainty over its benefit in ‘real world’ clinical  practice12,13. The aim of this study was to 
characterize the use of DHC and its relation to clinical outcomes in thrombolyzed AIS patients who participated 
in the international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).
Methods
Study design. ENCHANTED was an international, multicenter, prospective, partial-factorial, randomized, 
open, blinded-endpoint trial that investigated the effectiveness of low-dose (0.6 mg/kg) versus standard-dose 
(0.9 mg/kg) intravenous alteplase and intensive (systolic target < 140 mmHg) versus standard (< 180 mmHg) 
blood pressure (BP) lowering in 4557 thrombolysis-eligible and treated AIS patients between March 2012 and 
April  201814–18. Patients were recruited at 111 clinical centers in five Asian countries (including China, Korea, 
Vietnam) and seven non-Asian countries (including United Kingdom, Brazil, Chile). Patients could participate 
in one or both arms of the study, according to inclusion/exclusion criteria, on a background of management 
according to best practice guidelines. The study was approved by the ethics committees of participating cent-
ers (see Supplementary list)16, and all patients (or legally appropriate surrogates) provided written informed 
consent. All methods were performed in accordance with the relevant guidelines and regulations. The study is 
registered at Clinicaltrials.gov (NCT01422616).
Procedures. Demographic, medical history, and clinical characteristic data, including the severity of neuro-
logical impairment on the National Institute of Health Stroke Scale (NIHSS), were obtained at the time of enroll-
ment (baseline). Imaging data on computerized tomography (CT), magnetic resonance imaging (MRI), and 
angiography were collected in DICOM format, anonymized, and centrally analyzed by at least two independent 
expert assessors blind to clinical information and treatment assignments. DHC was defined as hemicraniectomy 
or decompressive surgery recorded on the study case record form at 7 days (or hospital discharge, if sooner) or 
as reported according to standard criteria for a serious adverse event (SAE) to the end of the 90-day follow-up. 
In the case of multiple SAEs, only SAEs related to surgical decompression were included in the analyses. All 
patients not known to have died were followed up in-person or by telephone by trained independent research-
ers at 90 days post-randomization. The primary outcome for these analyses was death or any disability, defined 
by scores 2–6 on the modified Rankin scale (mRS). Other outcomes included death/major disability and death 
(mRS scores 3–6 and 6, respectively).
Statistical analysis. Predictors of DHC were assessed in multivariable logistic regression models that 
included age, sex, Asian ethnicity, and all significant variables (P < 0.05) in univariable analysis. Considering 
disequilibrium and unbalanced variables between two groups, a propensity score analysis was also undertaken 
whereby a propensity score for each subject was obtained in a logistic regression model that included age, sex, 
ethnicity (Asian vs. non-Asian), hypertension, atrial fibrillation, antithrombotic therapy, lipid-lowering therapy, 
baseline NIHSS score, and a final diagnosis of large artery occlusion due to significant atheroma. The inverse 
probability of treatment weighting (IPTW) was used as the primary strategy to balance the baseline  data19, 
which was examined using an absolute standardized mean difference within an acceptable margin of 0.220, indi-
cating well-balanced distributions of covariates (see Supplementary Fig. S1 online). Stabilized weights were then 
incorporated into logistic regression models to determine associations of surgical intervention and outcomes. 
Data are reported with odds ratio (OR) and 95% confidence interval (CI). A 2-sided P value < 0.05 was set as a 
standard level of significance. All analyses were performed using SAS 9.3 software (SAS Institute, North Caro-
lina, US).
Results
Of 4557 included patients (2350, 1280, 947 in Arms A, B, and A + B, respectively), 95 (2.1%) underwent DHC. 
Of these surgical patients, the timing of intervention for 74 (78%) was within 6 days of randomization, including 
73 (99% with available data of timing) who underwent DHC within two days of neurological deterioration (see 
Supplementary Fig. S2 online). The indications for DHC were malignant brain edema with/without mass effect 
(36, 38%), and ICH (27, 28%), with 32 (34%) patients without such information. Table 1 shows that compared 
to other patients, those who underwent DHC were more likely to be of non-Asian ethnicity, have a history of 
hypertension, hypercholesterolemia, and prior use of lipid-lowering therapy, higher baseline NIHSS score, and 
a final diagnosis of proximal cerebral vessel occlusion identified on CT/MRI angiography. After applying IPTW 
with a stabilized weight method, only three baseline categorical covariates (atrial fibrillation, prior antithrom-
botic therapy, and lipid-lowering therapy) were not well balanced between the two groups (all P < 0.05) (Table 1).
Table 2 shows the independent predictors for DHC were younger age (OR 0.98, 95% CI 0.96–0.99; P < 0.01), 
non-Asian ethnicity (OR 0.49, 95% CI 0.30–0.79; P < 0.01), lipid-lowering therapy (OR 2.11, 95% CI 1.29–3.46; 
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P < 0.01), severe neurological impairment (OR 1.08, 95% CI 1.05–1.10; P < 0.01), and large artery occlusive AIS 
(OR 2.37, 95% CI 1.52–3.70; P < 0.01).
During the first seven days of hospital admission, patients who underwent DHC had more cerebral angio-
grams, intravenous BP lowering treatment, admission to monitored and organized care areas (i.e., intensive care 
unit), and other interventions (intubation and ventilation, treatment of pyrexia, nasogastric feeding, and use of 
compression stockings for venous thromboembolism prophylaxis), but had less use of traditional intravenous 
Chinese medicine (Table 3).
Overall, there were 2231 (49.0%) patients who were either dead or disabled at 90 days. When compared to 
other patients, those who received DHC had worse patterns of recovery with 82% death or dependency (Table 4; 
Fig. 1). There were no differences in clinical outcomes between patients with low-dose versus standard-dose 
intravenous alteplase treatment prior to DHC (see Supplementary Table S1 online). Amongst all 4557 in the trial, 
81 (2%) patients had ICH based on SITS-MOST criteria, and this had occurred before DHC in these patients 
(27, 28%).
Discussion
In this study, derived from an international multicenter clinical trial database, we have shown that approximately 
only one in 50 thrombolyzed AIS patients receive DHC treatment. Compared to other patients, those who 
received DHC were significantly younger, of non-Asian ethnicity, more often on lipid-lowering therapy, had 
a severe neurological impairment, and an AIS due to large vessel occlusion. Despite receiving this life-saving 
intervention and high use of ancillary management strategies, DHC patients had a poor prognosis due to their 
severe form of AIS.
The pattern of surgical intervention for AIS has changed as EVT has evolved since the first randomized 
controlled trials were published in 2014 and 2015. Nationwide US trends suggest EVT has increased from 3.4 
Table 1.  Baseline characteristics in relation to decompressive hemicraniectomy for acute ischemic stroke, 
according to the use of inverse probability of treatment weighting. Data are n (%), mean (SD), or median 
(IQR). BP blood pressure, CT computed tomography, MRI magnetic resonance imaging, NIHSS National 
Institute of Health Stroke Scale. *P values based on χ2 test, Fisher’s exact test, or Wilcoxon test. † Not applicable 









Yes (n = 95) No (n = 4462) Yes (n = 87) No (n = 4349)
Time from stroke onset to randomization, h 2.8 (2.2–3.9) 2.9 (2.1–3.7) 0.75 3.5 (2.4–4.3) 2.9 (2.1–3.7) −†
Age, year 65 (11) 66 (13) 0.23 68 (11) 66 (13) −†
Female 31 (32.6) 1691 (37.9) 0.30 30 (34.5) 1640 (37.7) 0.57
Asian ethnicity 51 (53.7) 2968 (66.5) 0.01 53 (60.9) 2894 (66.5) 0.27
Hypertension 71/95 (74.7) 2866/4451 (64.4) 0.04 62 (71.3) 2813 (64.7) 0.20
Previous stroke 12 (12.6) 811 (18.2) 0.17 9 (10.3) 793 (18.2) 0.08
Atrial fibrillation 23/95 (24.2) 785/4447 (17.7) 0.10 22 (25.3) 763 (17.5) 0.04
Coronary artery or other heart diseases 25/95 (26.3) 886/4451 (19.9) 0.12 21 (24.1) 855 (19.7) 0.29
Diabetes mellitus 21/95 (22.1) 907/4451 (20.4) 0.68 12 (13.8) 889 (20.4) 0.15
Hypercholesterolemia 23/95 (24.2) 684/4451 (15.4) 0.02 17 (19.5) 675 (15.5) 0.31
Current smoker 25/95 (26.3) 983/4445 (22.1) 0.33 16/87 (18.4) 957/4345 (22.0) 0.36
Pre-stroke absence of symptoms 78/94 (83.0) 3700/4449 (83.2) 0.96 73/85 (85.9) 3633/4348 (83.6) 0.60
Antihypertensive therapy 52 (54.7) 2092 (46.9) 0.13 47 (54.0) 2042 (47.0) 0.21
Antithrombotic therapy 30/94 (31.9) 1043/4449 (23.4) 0.06 31 (35.6) 1024 (23.5) 0.01
Lipid-lowering therapy 29/94 (30.9) 817/4448 (18.4) < 0.01 25 (28.7) 811 (18.6) 0.02
Systolic BP, mmHg 153 (18) 153 (19) 0.68 156 (16) 153 (19) –†
NIHSS score 13 (6–17) 8 (5–13) < 0.01 8 (5–14) 8 (5–13) –†
NIHSS score ≥ 15 38 (40.0) 889 (19.9) < 0.01 21 (24.1) 865 (19.9) 0.38
Cerebral infarction with mass effect 3/95 (3.2) 55/4451 (1.2) 0.12 2 (2.3) 53 (1.2) 0.63
Proximal clot on CT/MRI angiogram 29/94 (30.9) 597/4409 (13.5) < 0.01 13 (14.9) 603 (13.9) 0.73
Final diagnosis
Large artery occlusion from atheroma 53/94 (56.4) 1751/4400 (39.8)
< 0.01
31 (35.6) 1748 (40.2)
0.21
Small vessel lacunar disease 4/94 (4.3) 1053/4400 (23.9) 15 (17.28) 1026 (23.6)
Cardioembolism 18/94 (19.1) 782/4400 (17.8) 18 (20.7) 768 (17.7)
Other 19/94 (20.2) 814/4400 (18.5) 22 (25.3) 807 (18.6)
Randomized low-dose alteplase 32/66 (48.5) 1618/3220 (50.2) 0.78 20/47 (42.6) 1568/3128 (50.1) 0.55
Randomized intensive BP lowering 18/42 (42.9) 1063/2154 (49.4) 0.41 24/51 (47.1) 1045/2112 (49.5) 0.81
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to 9.8% from 2012 to 2016, whereas DHC for those with malignant cerebral edema has declined from 11.4 to 
4.8%21. A retrospective study in Germany has also observed a near 50% reduction, from 17.4 to 8.2%, in DHC 
after the introduction of stent retrievers for  AIS22. The low frequency (2.1%) of DHC in our study likely reflects 
the selection of thrombolyzed AIS patients for a clinical trial, but the true rate may be even lower following the 
introduction of EVT in routine clinical practice.
Table 2.  Independent predictors associated with decompressive hemicraniectomy. aOR adjusted odds ratio, 
BP blood pressure, CI confidence interval, NIHSS National Institute of Health Stroke Scale, OR odds ratio. 
*Included all significant variables in univariable analysis, and age, sex, and Asian ethnicity.
Decompressive hemicraniectomy
OR (95% CI) P value aOR (95% CI)* P value
Time from onset to randomization, h 1.04 (0.86–1.26) 0.66
Age, year 0.99 (0.98–1.01) 0.31 0.98 (0.96–0.99) < 0.01
Female 0.79 (0.52–1.22) 0.30
Asian ethnicity 0.58 (0.39–0.88) 0.01 0.49 (0.30–0.79) < 0.01
Hypertension 1.64 (1.03–2.61) 0.04
Previous stroke 0.65 (0.35–1.20) 0.17
Atrial fibrillation 1.49 (0.93–2.40) 0.10
Coronary artery and other heart diseases 1.44 (0.91–2.28) 0.12
Diabetes mellitus 1.11 (0.68–1.81) 0.68
Hypercholesterolemia 1.76 (1.09–2.83) 0.02
Current smoker 1.26 (0.79–2.00) 0.33
Prestroke absence of symptoms 1.01 (0.59–1.75) 0.96
Antihypertensive therapy 1.37 (0.91–2.06) 0.13
Antithrombotic therapy 1.53 (0.99–2.38) 0.06
Lipid-lowering therapy 1.98 (1.27–3.09) < 0.01 2.11 (1.29–3.46) < 0.01
Systolic BP, mmHg 1.00 (0.99–1.01) 0.77
NIHSS score 1.07 (1.04–1.10) < 0.01 1.08 (1.05–1.10) < 0.01
Cerebral infarction with mass effect 2.61 (0.80–8.48) 0.11
Large artery occlusion due to significant atheroma 1.96 (1.30–2.95) < 0.01 2.37 (1.52–3.70) < 0.01
Table 3.  Other management in the first 7 days of hospital admission. Data are n (%) or mean (SD). BP 




P value*Yes (n = 95) No (n = 4462)
Cerebral angiogram 13/95 (13.7) 243/4451 (5.5) < 0.01
Intra-arterial alteplase 2/13 (15.4) 34/242 (14.1) 0.89
Any IV BP lowering in first 24 h 20/40 (50.0) 668/1381 (48.3) 0.83
Any IV BP lowering in days 2–7 37/93 (39.8) 924/4380 (21.1) < 0.01
Systolic BP at 24 h 140 (21) 138 (19) 0.01
Intubation and ventilation 48/92 (52.2) 179/4381 (4.1) < 0.01
Fever occurrence 47/92 (51.1) 765/4380 (17.5) < 0.01
Fever treated 43/88 (48.9) 646/3964 (16.3) < 0.01
Nasogastric feeding 54/92 (58.7) 737/4380 (16.8) < 0.01
Mobilization by physiotherapist 47/92 (51.1) 1926/4380 (44.0) 0.17
Compression stockings 21/92 (22.8) 363/4379 (8.3) < 0.01
Subcutaneous heparin 20/95 (21.1) 841/4462 (18.9) 0.59
Any antithrombotic agent in first 24 h 17/95 (17.9) 730/4445 (16.4) 0.70
Traditional IV Chinese medicine 11/92 (12.0) 1421/4380 (32.4) < 0.01
IV corticosteroids 3/92 (3.3) 89/4380 (2.0) 0.44
Acute stroke unit admission 58/93 (62.4) 2432/4380 (55.5) 0.19
ICU admission 58/93 (62.4) 943/4379 (21.5) < 0.01
Any rehabilitation given 40/92 (43.5) 2183/4381 (49.8) 0.23
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As outlined in the most recent American Heart Association/American Stroke Association (AHA/ASA) guide-
lines, DHC is recommended for AIS patients who deteriorate neurologically from malignant brain swelling from 
middle cerebral artery infarction within 48 h despite medical  therapy6. In addition to brain swelling, our study 
found that ICH and mass effect were the two key clinical indications of DHC. Regarding the timing of surgery, 
19% of patients underwent surgery ≥ 7 days after their randomization because these patients had delayed neu-
rological deterioration later than 7 days after randomization, which required DHC intervention. However, DHC 
was performed on these patients as an emergent intervention within 48 h of neurological deterioration. Thus, 
decisions over the use of DHC and other surgical and medical management were according to the attending 
clinician’s decision based on the available resources, family wishes, and clinical practice in the context of local 
interpretation of guideline recommendations.
Our study demonstrated that factors associated with DHC included younger age, severe neurological impair-
ment, non-Asian ethnicity, and prior use of lipid-lowering therapy. Considering widely accepted indications 
for DHC in clinical practice and the literature, the former two criteria are not surprising. It is not clear why an 
association was found for non-Asian ethnicity and DHC. Although differing stroke pathology and mechanisms 
between Asians and non-Asians is a possible explanation, the association remained in analyses limited to large 
vessel occlusion. Other explanations for non-Asian ethnicity and prior use of lipid-lowering therapy include 
chance and residual confounding in relation to the limitations of these secondary subgroup analyses.
Despite the short serum half-life of rt-PA (4–6 min), its fibrinolytic effect may last up to 24–48  h23. As 
symptomatic ICH is the most severe complication of intravenous thrombolysis with rt-PA24, a major concern 
in the subsequent use of DHC is the potential for perioperative ICH. Although young to middle-aged patients 
appear to derive the main benefits of DHC in malignant hemispheric AIS, the randomized evidence is from non-
thrombolyzed  patients7–11. There were few studies with small numbers of patients that suggest post-thrombolysis 
(single 0.6 mg/kg dose, not exceeding 60 mg) DHC is safe and without an apparent excess of  ICH25–28. Our study 
of older patients (mean age 66 years) suggests a poor outcome for DHC patients after thrombolysis, but the out-
comes are compatible with prior DHC trials. Moreover, there was no apparent differential influence of the dose 
Table 4.  Decompressive hemicraniectomy and clinical outcomes at 90 days. CI confidence interval, mRS 
modified Rankin scale, OR odds ratio. *The mRS evaluates global disability; scores range from 0 (no 
symptoms) to 6 (death). A score of 2 to 5 indicates some degree of disability.
Decompressive 
hemicraniectomy Multivariate regression Propensity score
Yes (n = 93) No (n = 4365) OR (95% CI) P value OR (95% CI) P value
Death/disability (mRS 2–6)* 76 (81.7) 2155 (49.4) 3.53 (1.99–6.27) < 0.01 3.86 (2.29–6.51) < 0.01
Death/major disability (mRS 3–6)* 72 (77.4) 1518 (34.8) 5.74 (3.35–9.82) < 0.01 4.40 (2.76–7.02) < 0.01
Death (mRS 6)* 31 (33.3) 381 (8.7) 5.43 (3.28–8.97) < 0.01 4.95 (3.07–7.98) < 0.01
Shift in mRS scores* 4.90 (3.34–7.18) < 0.01 4.89 (3.34–7.16) < 0.01
0 6 (6.5) 1144 (26.2)
1 11 (11.8) 1066 (24.4)
2 4 (4.3) 637 (14.6)
3 8 (8.6) 516 (11.8)
4 16 (17.2) 403 (9.2)
5 17 (18.3) 218 (5.0)
6 31 (33.3) 381 (8.7)
Figure 1.  Functional outcomes on the modified Rankin scale at 90 days by groups. The figure shows the 
distribution of scores on the modified Rankin scale at 90 days with scores ranging from 0 to 6. CI confidence 
interval, OR odds ratio, mRS modified Rankin scale.
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of rt-PA on outcomes from DHC, but the numbers are small and there is likely to be indication bias and residual 
confounding complicating our data. While the frequency of symptomatic ICH after thrombolysis ranges from 
2 to 7% in prospective stroke  registries29, the figure for hemorrhagic transformation of a large ischemic lesion 
is much higher in those who proceed to DHC in  AIS27,30. Furthermore, a recent study has shown similar rates 
of hemorrhagic transformation in those who had DHC where they had received thrombolysis or not (64.3% 
versus 66.7%; P = 0.906)25. Yet, our results showed a big difference in ICH rates for those who underwent DHC 
(28.4%) versus those who did not (1.2%), demonstrating that ICH was considered as an indication for DHC by 
the local clinicians.
The strengths of our study are the inclusion of a broad range of patients from different health care settings 
globally who had systematic prospective assessments as part of a clinical trial. Another novel aspect of this study 
is providing evidence of the effects of DHC in the context of thrombolyzed and older patients. However, while 
we undertook both multivariable and propensity score adjusted analyses, the overall numbers of DHC patients 
were small and limited our ability to completely adjust for baseline prognostic variables. Moreover, these analyses 
were post-hoc, non-randomized, and derived from a clinical trial population of thrombolyzed AIS patients with 
predominantly mild-moderate neurological severity, and data on DHC indications were based on reporting by 
the investigators rather than primary data collected as part of the trial. Unfortunately, detailed information on 
early ischemic change and hemorrhagic transformation of the infarct was lacking, except for the Alberta Stroke 
Program Early CT Score (ASPECTS) for participants in Arm A (see Supplementary Fig. S2 online). These find-
ings therefore need to be interpreted with caution.
Conclusions
In summary, our analysis of a large and broad range of thrombolyzed AIS patients has shown that DHC is asso-
ciated with a poor outcome in those who receive this intervention for severe neurological deterioration. These 
data may guide clinical decision-making and the counseling of patients and family members.
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author 
upon reasonable request.
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